CANDESARTAN TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CANDESARTAN CILEXETIL

Saadav alates:

PRO DOC LIMITEE

ATC kood:

C09CA06

INN (Rahvusvaheline Nimetus):

CANDESARTAN

Annus:

32MG

Ravimvorm:

TABLET

Koostis:

CANDESARTAN CILEXETIL 32MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0135220004; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2014-04-14

Toote omadused

_ _
_Candesartan _
_Page 1 of 35_
PRODUCT MONOGRAPH
PR
CANDESARTAN
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Manufacturer's Standard
Angiotensin II AT
1
Receptor Blocker
Pro Doc Ltée
Date of Revision:
2925, boul. Industriel November 10, 2021
Laval, Quebec
H7L 3W9
Submission Control No.: 257568
_ _
_Candesartan _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS
AND
PRECAUTIONS
..........................................................................................
4
ADVERSE
REACTIONS
............................................................................................................
8
DRUG
INTERACTIONS
...........................................................................................................
12
DOSAGE
AND
ADMINISTRATION
.......................................................................................
14
OVERDOSAGE
.........................................................................................................................
17
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
17
STORAGE
AND
STABILITY...................................................................................................
19
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 19
PART II: SCIENTIFIC INFORMATION
................................................................................
21
PHARMACEUTICAL
INFORMATION
..................................................................................
21
CLINICAL
TRIALS
...........................